Orally Dissolving Tablet (ODT) Excipients Market Size, Share, Growth and Industry Analysis by Type (Binders, Glidants, Diluents, Disintegrants, Sweeteners, And, Others) By Application (Anti-Psychotics Drug, Anti-Epileptics Drug, And, Others), Regional Insights and Forecast From 2025 To 2033

Last Updated: 14 July 2025
SKU ID: 20350563

Trending Insights

Report Icon 1

Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities

Report Icon 2

Our Research is the Cornerstone of 1000 Firms to Stay in the Lead

Report Icon 3

1000 Top Companies Partner with Us to Explore Fresh Revenue Channels

ORALLY DISSOLVING TABLET (ODT) EXCIPIENTS MARKET OVERVIEW

The global orally dissolving tablet (ODT) excipients market size was projected at USD 18.48 billion in 2024 and is expected to hit USD 25.01 billion by 2033 with a CAGR of 3.4% during the forecast period from 2025 to 2033.

Orally dissolving tablet (ODT) excipients are essential components that enable the rapid disintegration and dissolution of medication in the oral cavity. These excipients, often including superdisintegrants like crospovidone or sodium starch glycolate, along with sweeteners, flavors, and binders, contribute to the ODT's quick breakdown upon contact with saliva.

This unique formulation enhances patient convenience and compliance, particularly for individuals who have difficulty swallowing traditional tablets or capsules. ODT excipients play a pivotal role in ensuring effective drug delivery through this user-friendly dosage form. All of the above-mentioned factors have helped tremendously in increasing the orally dissolving tablet (ODT) excipients market share.

COVID-19 IMPACT

Alteration in Production Timelines Due to Increased Hygiene During Pandemic Hindered Market Growth

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden spike in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

The pandemic of COVID-19 resulted in lockdowns and social distancing norms. The emergence of COVID-19 has impacted the production and supply chain of orally dissolving tablet (ODT) excipients. Disruptions in global transportation, limited availability of raw materials, and workforce challenges have led to fluctuations in excipient procurement and pricing.

Additionally, increased hygiene and safety measures within manufacturing facilities have altered production timelines. Some excipient manufacturers have adapted to these challenges by diversifying sourcing options and implementing remote work solutions. Despite these hurdles, the pharmaceutical industry's resilience and adaptability have enabled the continued production of ODTs. Due to the several challenges faced during the pandemic, the market value declined.

LATEST TRENDS

Improved Drug Solubility Provided by Nano-technology-based Excipients to Increase Market Growth

Recent innovations in orally dissolving tablet (ODT) excipients have focused on enhancing dissolution rates, taste masking, and stability. Nanotechnology-based excipients offer improved drug solubility and rapid disintegration, resulting in faster onset of action. Encapsulation techniques are being explored for effective taste masking, making medications more palatable for patients.

Novel polymers and co-processed excipients are addressing stability concerns, extending shelf life without compromising ODT performance. Furthermore, the integration of natural, plant-based materials aligns with growing consumer preference for clean label products. These innovations collectively enhance the overall patient experience, compliance, and efficacy of ODT formulations in pharmaceuticals, catering to evolving healthcare demands.

Orally-Dissolving-Tablet-Excipients-Market-By-Types,-2033

ask for customizationRequest a Free sample to learn more about this report

ORALLY DISSOLVING TABLET (ODT) EXCIPIENTS MARKET SEGMENTATION

By Type

The market can be divided on the basis of type into the following segments:

Binders, glidents, diluents, disintegrants, sweeteners, and, others. The blinders segment is anticipated to dominate the market during the forecast period.

By Application

Classification based on application into the following segment:

Anti-psychotics drug, anti-epileptics drug, and, others. The anti-psychotics segment is predicted to dominate the market during the research and forecast period.

DRIVING FACTORS

Patient Preference for Convenient and User-friendly Dosage to Accelerate Market Growth

Several driving factors are shaping advancements in orally dissolving tablet (ODT) excipients. Patient preference for convenient and user-friendly dosage forms is a key driver, propelling research into ODT excipients that ensure rapid disintegration, enhanced drug delivery, and improved taste masking.

The pharmaceutical industry's focus on pediatric and geriatric populations, who often face swallowing challenges, spurs the development of excipients that cater to their needs. Regulatory support for innovative drug delivery systems further encourages ODT excipient innovations. Moreover, the demand for personalized medicine and the growing market for over-the-counter medications underscore the importance of excipients that enable efficient and effective ODT formulations. These factors are playing an important role in increasing the market growth and development.

Potential for Line Extensions of Existing Medications into ODT formulations to Propel Market Growth

Aside from patient preferences and ease of use, several other driving factors influence the advancement of orally dissolving tablet (ODT) excipients. Rapid onset of action and improved bioavailability due to the quick dissolution of ODTs attract pharmaceutical companies seeking competitive advantages. ODTs also offer enhanced medication adherence, especially for pediatric and geriatric patients, potentially leading to better treatment outcomes.

 The potential for line extensions of existing medications into ODT formulations drives innovation, expanding market reach. Furthermore, the increasing demand for personalized medicine opens avenues for ODT excipients that enable tailored dosing. These multifaceted factors collectively stimulate research and development in the field of ODT excipients.  These factors are promoting the orally dissolving tablet (ODT) excipients market growth.

RESTRAINING FACTOR

Limited Compatibility Between Excipients and Other Medications to Decrease Market Growth

Several restraining factors hinder the progress of orally dissolving tablet (ODT) excipient innovations. Limited compatibility between excipients and active pharmaceutical ingredients (APIs) can pose formulation challenges, leading to compromised efficacy and stability. The need for specialized equipment and technologies to manufacture ODTs may increase production costs.

Regulatory constraints and safety concerns regarding excipient use can impede rapid adoption. Additionally, achieving consistent taste masking and texture in ODTs remains a complex task. Intellectual property issues related to novel excipient development can deter investment. Addressing these challenges requires collaborative efforts among pharmaceutical researchers, manufacturers, and regulatory bodies to ensure the successful integration of ODT excipients into modern drug delivery systems.

ORALLY DISSOLVING TABLET (ODT) EXCIPIENTS MARKET REGIONAL INSIGHTS

North America to Dominate Market Share in Upcoming Years

North America stands as the leading region in the development and adoption of orally dissolving tablet (ODT) excipients. The region's advanced pharmaceutical industry infrastructure, robust research and development capabilities, and favorable regulatory environment contribute to its prominence.

Leading pharmaceutical companies and research institutions in North America continually invest in ODT technology, resulting in innovative excipient formulations that cater to patient preferences and needs. Additionally, the region's high healthcare awareness, significant patient demand for user-friendly medication options, and willingness to adopt novel drug delivery methods further solidify North America's position as a frontrunner in ODT excipient advancements.

KEY INDUSTRY PLAYERS

Leading Players adopt Acquisition Strategies to Stay Competitive

Several players in the market are using acquisition strategies to build their business portfolio and strengthen their market position. In addition, partnerships and collaborations are among the common strategies adopted by companies. Key market players are making R&D investments to bring advanced technologies and solutions to the market.

List of Top Orally Dissolving Tablet (ODT) Excipients Companies

  • BASF (Germany)
  • JRS Pharma (Switzerland)
  • Roquette (France)
  • ABF Ingredients (U.K.)
  • DFE Pharma (Netherlands)
  • Evonik (Germany)
  • Merck KGaA (Germany)
  • Ashland (U.S.)
  • Meggle Pharma (Germany)
  • Shin-Etsu (Japan)
  • Fuji Chemical Industries (Japan)
  • McePharma (Vivesa holding) (Czech Republic)
  • Cargill Incorporated (U.S.)
  • Daicel Corporation (Japan)
  • Anhui Sunhere Pharmaceutical (China)

REPORT COVERAGE

The report provides an insight into the industry from both the demand and supply sides. Further, it also gives information on the impact of COVID-19 on the market, the driving and the restraining factors along with the regional insights. Market dynamic forces during the forecast period have also been discussed for the better understanding of the market situations

Orally Dissolving Tablet (ODT) Excipients Market Report Scope & Segmentation

Attributes Details

Market Size Value In

US$ 18.48 Billion in 2024

Market Size Value By

US$ 25.01 Billion by 2033

Growth Rate

CAGR of 3.4% from 2025 to 2033

Forecast Period

2025-2033

Base Year

2024

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type

  • Binders
  • Glidents
  • Diluents
  • Disintegrants
  • Sweeteners
  • Others

By Application

  • Anti-Psychotics Drug
  • Anti-Epileptics Drug
  • Others

FAQs